The Executive Order directs the Secretary of HHS to communicate most-favored-nation, or MFN, price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. The implications of these actions remain unclear and are likely to result in litigation if the administration pursues an MFN regulatory pricing requirement.
All entries for: Ironwood Pharmaceuticals, Inc.
February 26, 2026
Ironwood Pharmaceuticals, Inc.
Neutral Outlook
Boston, MA
201-500 employees
As another example, the Inflation Reduction Act, or IRA, of 2022, contains various drug pricing and payment provisions. Among other provisions, the IRA imposes a yearly cap ($2,000 in 2025) on out-of-pocket prescription drug prices in Medicare Part D.
Disease Area: Gastrointestinal, Rare Diseases
Drug Type: Biologic, Small Molecule